Azoy Alexander 4

What Happened

• Azoy Alexander, Chief Accounting Officer of Arcus Biosciences, received a grant of restricted stock units (RSUs) on Jan 23, 2026: 21,050 RSUs and an additional 14,050 RSUs recorded as a derivative award (total 35,100 RSUs). Both grants were reported at $0.00 per share (no cash paid). This is an award/compensation event (not a purchase or sale).

Key Details

• Transaction date: 2026-01-23. Form filed: 2026-01-26 (filed within the normal two-business-day window).
• Reported entries: 21,050 shares @ $0.00 (Acquired); 14,050 shares @ $0.00 (Acquired, Derivative).
• Vesting: Per footnote F1, the RSUs vest in four equal annual installments beginning December 15, 2026, subject to continued service.
• Footnotes: F2 notes these entries include the unvested portion of the Reporting Person’s RSU grants. F3 references an option becoming exercisable in 48 equal monthly installments after Jan 1, 2026 (relates to other option holdings disclosed).
• Shares owned after transaction: not specified in the provided filing details.
• Transaction code: A = Award/Grant. No sales, purchases, or immediate transfers reported.

Context

• RSU awards are typical compensation/retention tools and do not indicate an immediate purchase or sale of stock. The derivative designation simply means those RSUs are contingent/unvested and convert to common shares only as they vest.